TC
CORT icon

Truvestments Capital’s Corcept Therapeutics CORT Stock Holding History

Truvestments Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11K Hold
13
– – ﹤0.01% 1046
2026
Q1 		$513 Hold
13
– – ﹤0.01% 1090
2025
Q4 		$443 Buy
13
+12
+1,200% +$943 ﹤0.01% 957
2025
Q3 		$61 Hold
1
– – ﹤0.01% 1004
2025
Q2 		$54 Buy
+1
New +$73 ﹤0.01% 937

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Truvestments Capital's CORT Position: Q2 2026 in Review

Truvestments Capital held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 13 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #1046.

Truvestments Capital first reported a position in CORT in Q2 2025 and has held it in 5 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Truvestments Capital held 13 shares of Corcept Therapeutics worth $1.11K as of Q2 2026.
  • Truvestments Capital left its Corcept Therapeutics share count unchanged in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #1046 holding.
  • Truvestments Capital first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.